secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2024-07-15T23:59:59+00:00
Accession:  0001193125-24-178827
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences enters $60M ATM equity facility; prelim Q2 net loss $10.7-12.7M
--------------------------------------------------------------------------------

- Up to $60M at-the-market offering via Canaccord Genuity and Needham; commission up to 3%.
- Preliminary Q2 2024 cash and cash equivalents $26.0-26.5M (excl. $60M rights offering close in July).
- GAAP net loss $10.7-12.7M; non-GAAP net loss $8.7-9.7M.
- GAAP costs and expenses $11-13M; non-GAAP costs $9-10M; adjustments include stock-based comp and D&A.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000119312524178827/0001193125-24-178827-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000119312524178827/d867904d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-178827

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer